| pubmed-article:9514058 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9514058 | lifeskim:mentions | umls-concept:C1335749 | lld:lifeskim |
| pubmed-article:9514058 | lifeskim:mentions | umls-concept:C1709900 | lld:lifeskim |
| pubmed-article:9514058 | lifeskim:mentions | umls-concept:C1514559 | lld:lifeskim |
| pubmed-article:9514058 | lifeskim:mentions | umls-concept:C0080055 | lld:lifeskim |
| pubmed-article:9514058 | lifeskim:mentions | umls-concept:C0111429 | lld:lifeskim |
| pubmed-article:9514058 | lifeskim:mentions | umls-concept:C0237881 | lld:lifeskim |
| pubmed-article:9514058 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:9514058 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
| pubmed-article:9514058 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9514058 | pubmed:dateCreated | 1998-4-2 | lld:pubmed |
| pubmed-article:9514058 | pubmed:abstractText | Cyclin E gene alteration in the cell cycle plays an important role in carcinogenesis, while p53 protein affects different phase checkpoint pathways by activating p21WAF1/CIP1 in the normal cell cycle. We immunohistochemically examined the expression of cyclin E and p53 proteins in 121 patients with transitional cell carcinoma (TCC) of the renal pelvis and ureter to determine their significance for tumour behaviour and patient prognosis. Cyclin E and p53 immunostaining of the nucleus was observed in 36 tumours (29.8%) and 35 tumours (28.9%) respectively. A significant percentage, 69.4% (25 out of 36 tumours), of the cyclin E-positive tumours exhibited simultaneous labelling for p53 (P < 0.05). Mirror-section technique was performed in five selected double-positive tumours to identify cancer cells that were nuclei positive for both cyclin E and p53. The prevalence of cases simultaneously exhibiting both cyclin E and p53 immunostaining was higher in the high-grade tumours (P < 0.01) than in the other types of tumours. Patients with TCCs coexpressing cyclin E and p53 had a significantly poorer prognosis than those expressing neither cyclin E nor p53 (P < 0.001). These in vivo findings provide evidence for cyclin E protein overexpression in TCCs intimately associated with p53 alteration and suggest that simultaneous overexpression of both cyclin E and p53 is related to tumour behaviour and poor prognosis. | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9514058 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9514058 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9514058 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9514058 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:9514058 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:9514058 | pubmed:author | pubmed-author:YamamotoAA | lld:pubmed |
| pubmed-article:9514058 | pubmed:author | pubmed-author:OhtsukiYY | lld:pubmed |
| pubmed-article:9514058 | pubmed:author | pubmed-author:KuwaharaMM | lld:pubmed |
| pubmed-article:9514058 | pubmed:author | pubmed-author:SonobeHH | lld:pubmed |
| pubmed-article:9514058 | pubmed:author | pubmed-author:TeraoNN | lld:pubmed |
| pubmed-article:9514058 | pubmed:author | pubmed-author:ShuinTT | lld:pubmed |
| pubmed-article:9514058 | pubmed:author | pubmed-author:FurihataMM | lld:pubmed |
| pubmed-article:9514058 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9514058 | pubmed:volume | 77 | lld:pubmed |
| pubmed-article:9514058 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9514058 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9514058 | pubmed:pagination | 783-8 | lld:pubmed |
| pubmed-article:9514058 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:meshHeading | pubmed-meshheading:9514058-... | lld:pubmed |
| pubmed-article:9514058 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9514058 | pubmed:articleTitle | Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvis and ureter. | lld:pubmed |
| pubmed-article:9514058 | pubmed:affiliation | Department of Pathology II, Kochi Medical School, Nankoku, Japan. | lld:pubmed |
| pubmed-article:9514058 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9514058 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9514058 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9514058 | lld:pubmed |
